Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer
Recruiting · NCT06834152 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Zurich
View the official record on ClinicalTrials.gov →Interventions studied
radiotherapy
What this trial is about
The aim of this phase II international multicenter study is to evaluate the safety, feasibility, and efficacy of CT or MRI-adaptive SBRT, delivered in five weekly fractions, in patients with newly diagnosed localized prostate cancer who have lower urinary tract symptoms and/or prostatic hyperplasia.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- histologically confirmed localized prostate cancer
- planned treatment is SBRT according to standard of care and consists of definitive CT or MRI online adaptive SBRT of the prostate according to the PACE trial which includes a total dose to clinical target volume 1 (CTV1, i.e. prostate and proximal 1 cm of the seminal vesicle) of 40.0 Gy in 5 weekly fractions (single dose of 8.0 Gy) and total dose to planning target volume 1 (PTV1) of 37.5 Gy in 5 weekly fractions (single dose of 7.5 Gy) with a compromise for bowel sparing allowed. For patients with unfavorable intermediate to very high-risk disease (according to NCCN guidelines) a total dose to the planning target volume 2 (PTV2, i.e. proximal 1-2 cm of the seminal vesicle) of 32.5 Gy in 5 weekly fractions (single dose of 6.5 Gy) will be delivered.
- intermediate to (very) high risk localized prostate cancer (≤ cT3a and Gleason score ≤ 9 and/or PSA ≤ 20 ng/ml)
- prostate volume \> 60 cc and/or IPSS \> 12;
Exclusion criteria
- Very high risk localized prostate cancer with indication for ADT and ARPI (i.e. Gleason ≥ 8 and cT3a)
- Involvement of seminal vesicles (cT3b)
- Contraindications against definitive CT or MRI-adaptive radiotherapy of the prostate, e.g. inflammatory bowel disease (IBD); previous radiotherapy in the pelvis, previous local radiotherapy of the prostate, contraindication for MRI or CT;
- Patients with severe genitourinary symptoms (e.g. recent urinary retention ≥ grade 3 according CTCAE v.5.0);
- Lymph node metastases or distant metastases (i.e. no localised prostate cancer);
- Participation in a clinical trial which might influence the results of this project.
Where it is running
3 locations listed.
- Klinik für Radioonkologie und Strahlentherapie, Universitätsklinikum Heidelberg - Heidelberg, Baden-Wurttemberg, Germany
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum LMU - Munich, Bavaria, Germany
- University Hospital Zurich, Department of Radio-Oncology - Zurich, Canton of Zurich, Switzerland